Data Monitoring Committee Reports: Telling the Data's Story
- PMID: 39656431
- DOI: 10.1007/s43441-024-00727-1
Data Monitoring Committee Reports: Telling the Data's Story
Abstract
A Data Monitoring Committee (DMC) plays a pivotal role in monitoring participant safety and efficacy and overseeing the integrity of clinical trials. DMCs accomplish this mission by periodically reviewing accumulating data to assess benefits and harms of interventions in ongoing studies and making subsequent recommendations regarding future clinical trial conduct to the trial sponsor. Reports summarizing data from the clinical trial are prepared for the DMC by statistical and data analysis centers to inform DMC decision-making. In practice however, these reports are often disorganized, complex, and provide overwhelming detail yet insufficient information, that hinders accurate and efficient interpretation of interim data. This review paper delves into the nuances of preparing effective DMC reports, highlighting the importance of simplicity, clarity, and thoughtful relevance in data presentation. We discuss structured approaches for preparing closed reports, which deal with sensitive and sometimes messy interim data, and underscore the use of visual summaries and narrative elements that enhance comprehension and facilitate efficient assessments of trial data. The paper outlines key principles for preparing DMC reports and provides practical guidance on their structure. Ultimately, this guidance seeks to ensure that the data's story is clearly and efficiently conveyed to facilitate the DMC decision-making process.
Keywords: Benefit-risk; DMC; DSMB; Reporting; Reports.
© 2024. The Author(s), under exclusive licence to The Drug Information Association, Inc.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
Similar articles
-
Issues in data monitoring and interim analysis of trials.Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv. doi: 10.3310/hta9070. Health Technol Assess. 2005. PMID: 15763038 Review.
-
Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.J Biopharm Stat. 2014;24(5):968-75. doi: 10.1080/10543406.2014.925719. J Biopharm Stat. 2014. PMID: 24926941 Free PMC article.
-
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job.Ann Intern Med. 2020 Jan 21;172(2):119-125. doi: 10.7326/M19-1491. Epub 2019 Nov 19. Ann Intern Med. 2020. PMID: 31739312
-
On the independence of data monitoring committee in adaptive design clinical trials.J Biopharm Stat. 2012;22(4):853-67. doi: 10.1080/10543406.2012.676536. J Biopharm Stat. 2012. PMID: 22651119
-
The Case for Access to Data Monitoring Committee Charters.NEJM Evid. 2024 Sep;3(9):EVIDctw2400058. doi: 10.1056/EVIDctw2400058. Epub 2024 Aug 27. NEJM Evid. 2024. PMID: 39189859 Review.
References
-
- Evans SR. Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards. NEJM Evid. 2022;1:EVIDctw2100005. https://doi.org/10.1056/EVIDctw2100005
-
- Ellenberg SS, Fleming TR, DeMets DL. Responsibilities of the Data Monitoring Committee and Motivating Illustrations. Data Monitoring Committees in Clinical Trials. 2nd ed. Hoboken, NJ: John Wiley & Son Ltd; 2019. pp. 35–88.
-
- Evans SR, Ting N. Fundamental concepts for New Clinical trialists. Boca Raton, FL: Chapman and Hall/CRC; 2016.
-
- Herson J. Data and Safety Monitoring Committees in clinical trials. 2nd ed. New York: Chapman and Hall/CRC; 2016. - DOI
-
- Wittes J. Behind closed doors: the data monitoring board in randomized clinical trials. Stat Med. 1993;12:419–24. https://doi.org/10.1002/sim.4780120504 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical